James E. Flynn - 11 Aug 2025 SCHEDULE 13G Report for BridgeBio Oncology Therapeutics, Inc. Common Stock (HLXB)

Filing Manager
James E. Flynn
Reporting Manager
Deerfield Management Company, L.P.
Security
BridgeBio Oncology Therapeutics, Inc. Common Stock
Symbol
HLXB
Shares outstanding
79,180,648 shares
Disclosed Ownership
4,885,446 shares
Ownership
6.2%
Form type
SCHEDULE 13G
Filing time
18 Aug 2025, 17:59:19 UTC
Date of event
11 Aug 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"James E. Flynn disclosed 6.2% ownership in BridgeBio Oncology Therapeutics, Inc. Common Stock (HLXB) on 11 Aug 2025."

Quick Takeaways

  • James E. Flynn filed SCHEDULE 13G for BridgeBio Oncology Therapeutics, Inc. Common Stock (HLXB).
  • Disclosed ownership: 6.2%.
  • Date of event: 11 Aug 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 18 Aug 2025, 17:59.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (6)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Deerfield Mgmt, L.P. 3.1% 2,442,723 0 2,442,723 /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact
Deerfield Mgmt V, L.P. 3.1% 2,442,723 0 2,442,723 /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact
Deerfield Partners, L.P. 3.1% 2,442,723 0 2,442,723 /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact
Deerfield Private Design Fund V, L.P. 3.1% 2,442,723 0 2,442,723 /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact
Deerfield Management Company, L.P. 6.2% 4,885,446 0 4,885,446 /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact
James E. Flynn 6.2% 4,885,446 0 4,885,446 /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact

Sponsored